Japan GMP for Drugs and Quasi-drugs
Japan’s GMP standard: the Ministerial Order on the Standard of Manufacturing Control and Quality Control for Pharmaceuticals and Quasi-Pharmaceuticals, **MHLW Order No. 179 of 24 December 2004**, which wholly revised the 1999 predecessor (MHW Order No. 16). Its latest amendment is **MHLW Order No. 90 of 28 April 2021, in force 1 August 2021** — the revision that added the pharmaceutical quality system (Art. 3-3), stability monitoring (Art. 11-2) and product quality review (Art. 11-3). Note the division of labour Japan is easy to get wrong: **MHLW issues the ordinance; the PMDA conducts the GMP compliance inspection** and reports the result to the Ministry.
What this does not cover
stated in the document's own scope- Covers GMP for drugs and quasi-drugs; medical devices and regenerative products follow their own quality-system requirements under the PMD Act.
- Sets manufacturing GMP, not the marketing-authorisation decision, which is the separate review pathway under the PMD Act.
- Establishes the GMP ordinance, not the analytical test methods, which come from the Japanese Pharmacopoeia.
Always verify against the current published text before relying on it for a submission or inspection.
Overview
Japan’s GMP requirements are set out in the Ministerial Order on the Standard of Manufacturing Control and Quality Control for Pharmaceuticals and Quasi-Pharmaceuticals — MHLW Order No. 179 of 24 December 2004 — administered by the PMDA together with prefectural authorities. The order wholly revised its 1999 predecessor (MHW Order No. 16) and is organised by manufacturer and product class rather than by GMP topic: general provisions, then general rules for pharmaceutical manufacturing sites, then additional sections for active ingredients, sterile products and biological products, then a parallel chapter for quasi-pharmaceuticals. Its latest amendment, MHLW Order No. 90 of 28 April 2021 in force from 1 August 2021, is where the pharmaceutical quality system, stability monitoring and product quality review entered the text as express articles.
Scope & applicability
Manufacturing sites of pharmaceuticals and quasi-pharmaceuticals supplied to the Japanese market, including foreign manufacturers accredited under Article 13-3(1) of the Act. The ordinance is made under Article 14(2)(iv) of the Act on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145 of 1960, the former Pharmaceutical Affairs Act), so GMP compliance is a condition of marketing approval rather than a separate licence.
Legal basis & how it acquires force
The order is made under Article 14, paragraph (2), item (iv) of the Act on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145 of 1960 — the former Pharmaceutical Affairs Act), applied mutatis mutandis through Article 19-2, paragraph (5) for accredited foreign manufacturers. Because it is a ministerial order it has the force of regulation, not guidance, and compliance is a condition of marketing approval rather than a standalone licence. The division of labour is worth stating plainly: MHLW issues the order, and the PMDA conducts the GMP compliance inspection and reports the result to the Ministry.
Document structure
| Part | Covers |
|---|---|
| Chapter 1 — General Provisions (Arts. 1 to 3-2) | Purpose, definitions, and compliance with the product authorization requirements |
| Chapter 2 Section 1 — General Rules (Arts. 3-3 to 20) | Pharmaceutical quality system, production and quality departments, manufacturing supervisor, premises, validation, change and deviation management, records |
| Chapter 2 Section 2 — Active ingredients (Arts. 21 to 22) | Active ingredients treated as pharmaceuticals |
| Chapter 2 Section 3 — Sterile pharmaceuticals (Arts. 23 to 25) | Additional requirements for sterile manufacture |
| Chapter 2 Section 4 — Biological pharmaceuticals (Arts. 25-2 to 30) | Additional requirements for products of biological origin |
| Chapter 3 — Quasi-pharmaceuticals (Arts. 32 to 53) | The parallel regime for quasi-drug sites, their active ingredients, and sterile quasi-drugs |
Quick reference · How MHLW Order No. 179 is structured
The ordinance is organised by who manufactures and what they make, not by GMP topic. Find your section first: the general rules of Chapter 2 Section 1 are supplemented — never replaced — by the product-specific sections that follow.
| Chapter / Section | Articles | What it governs |
|---|---|---|
| Ch. 1 — General Provisions | 1 to 3-2 | Purpose, definitions, and compliance with the product authorization requirements |
| Ch. 2 §1 — General Rules | 3-3 to 20 | Pharmaceutical quality system, production and quality departments, manufacturing supervisor, premises, validation, change and deviation management |
| Ch. 2 §2 — Active ingredients | 21 to 22 | Active ingredients treated as pharmaceuticals |
| Ch. 2 §3 — Sterile pharmaceuticals | 23 to 25 | Additional requirements for sterile manufacture |
| Ch. 2 §4 — Biological pharmaceuticals | 25-2 to 30 | Additional requirements for biological products |
| Ch. 2 §5 — Miscellaneous | 31 | Exceptions to record retention |
| Ch. 3 — Quasi-pharmaceuticals | 32 to 53 | The parallel regime for quasi-drug manufacturers, including their APIs and sterile products |
Article 3-3 is the pharmaceutical quality system; Articles 11-2 and 11-3 are stability monitoring and product quality review. These were the substance of the 2021 amendment.
Source: MHLW Order No. 179 of 24 December 2004, latest amendment MHLW Order No. 90 of 28 April 2021 — PMDA tentative translation updated 21 June 2024. Verify against the current text before relying on it for a submission.
Key requirements
- Establish an effective pharmaceutical quality system with a documented quality policy (Art. 3-3)
- Manufacture in compliance with the product authorization requirements — the approved application is part of the GMP obligation (Art. 3-2)
- Run risk-based stability monitoring selected on assessed quality risk, through the quality department (Art. 11-2)
- Conduct product quality review regularly and as needed, reported in writing to the manufacturing supervisor (Art. 11-3)
- Apply the additional sterile and biological requirements of Chapter 2 §§3–4 on top of the general rules, not instead of them
Implementation tips
- Separate the two instruments before mapping anything: Order No. 179 is GMP at the manufacturing site, while market release certification of the finished product sits under GQP, MHLW Order No. 136 of 2004 — a different obligation on the marketing authorisation holder
- Expect periodic inspection every five years after approval, unless a product category-based GMP certificate (valid three years, introduced August 2021) covers the category
- Prepare application documents in Japanese — PMDA requires this even for foreign manufacturing sites, allowing only an overview in Japanese where the attachments are voluminous
- Read the PMDA tentative English translation as an aid, not as the instrument: PMDA states the Japanese original is authentic, and the translation of the 2021 amendment notification is still marked as under preparation
Revision notes
Order No. 179 of 24 December 2004 wholly revised the Regulation on Manufacturing Control and Quality Control for Pharmaceuticals and Quasi-Pharmaceuticals (MHW Order No. 16 of 1999). Its latest amendment is MHLW Order No. 90, made 28 April 2021 and in force from 1 August 2021. PMDA published a refreshed tentative English translation on 21 June 2024. Japan applied the PIC/S GMP Guide by administrative notice from 1 February 2012, two years before acceding to PIC/S in July 2014, where MHLW and PMDA count as a single participating authority.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
Japan is a founding region of the International Council for Harmonisation, and it applied the PIC/S GMP Guide by administrative notice from 1 February 2012 — two years before acceding to PIC/S in July 2014, where MHLW and the PMDA are counted as a single participating authority and the prefectures are represented by MHLW. The 2021 amendment reinforced that alignment by writing the pharmaceutical quality system, stability monitoring and product quality review into the order itself. Convergence supports comparability; the binding requirement for a Japanese site remains the MHLW order.
MHLW Ordinance No. 179: frequently asked questions
Quick answers to common questions about MHLW Ordinance No. 179.
Which instrument sets Japan’s GMP?
MHLW Order No. 179 of 24 December 2004, made under Article 14(2)(iv) of the Act on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices. It is a binding ministerial order; the PMDA and prefectural authorities administer it.
What is the current amendment to Order No. 179?
MHLW Order No. 90, made 28 April 2021 and in force from 1 August 2021. It added the pharmaceutical quality system (Art. 3-3), stability monitoring (Art. 11-2) and product quality review (Art. 11-3) as express articles.
Is Japan part of ICH and PIC/S?
Yes. Japan is a founding region of the ICH, and it acceded to PIC/S in July 2014 — MHLW and the PMDA count as one participating authority. Japan had already applied the PIC/S GMP Guide by administrative notice from 1 February 2012.
Is GMP compliance enough to release product in Japan?
No. Order No. 179 governs the manufacturing site. Certifying a batch for release to the Japanese market is a GQP obligation on the marketing licence holder under MHLW Order No. 136 of 2004 — a separate instrument and a separate party.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.